NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales momentum building. Dispensed cycles were up 2.5x July 2023 v July 2022 and up 80% in 2HFY23 vs 1HFY23 attributable to the positive impact of our refreshed leadership and marketing strategy.2 days agoMore than 3 fold revenue growth proves the company strategy success , with 75% reduction in marketing costs YOY , with the same rate , FY24 could reach 45 m to 50 Mil THEN so yes they are on the path to profitability . all indictors are positive .Share price outlook , if after the feb update that was 97 m worse the price reached 4.9 then after the +ve update expect 6 to 7 to 8.85 as per gauldman schs analysts
- Forums
- ASX - By Stock
- Generated positive operating cash flow
MYX
mayne pharma group limited
Add to My Watchlist
3.27%
!
$5.03

NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.03 |
Change
-0.170(3.27%) |
Mkt cap ! $408.6M |
Open | High | Low | Value | Volume |
$5.20 | $5.21 | $5.03 | $2.804M | 555.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14654 | $5.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.14 | 3111 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1198 | 5.020 |
1 | 1000 | 5.010 |
4 | 65885 | 5.000 |
2 | 2200 | 4.990 |
2 | 702 | 4.970 |
Price($) | Vol. | No. |
---|---|---|
5.140 | 3111 | 2 |
5.150 | 19052 | 1 |
5.180 | 1594 | 2 |
5.200 | 3198 | 2 |
5.220 | 1198 | 1 |
Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |